Medical Reasons for Same-Day Cancellations in Ophthalmic Surgery at a VA Hospital April Maa, MD and Brian R. Sullivan, MD
Case in Point Diabetic Ketoacidosis as a Presentation of Hemochromatosis Sondra Vazirani, MD, MPH and Mehran J. Kashefi, DO
Electronic Order Sets and Reminders Significantly Improve Ordering of Monitoring Parameters for Antipsychotic Medications Lindsey Marie Poker, PharmD; Margaret Mary Chrymko, PharmD; Jolene Renee Bostwick, PharmD, BCPS, BCPP
Editorial We're Losing the Battle! James V. Felicetta, MD
Cardiovascular Consult Collection Managing Acute Coronary Syndrome This supplement to Federal Practitioner on acute coronary syndrome (ACS), supported by the Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, was developed with the aim of helping primary care providers in federal practice
(especially those within the VA health care system) provide the highest quality care to their patients with ACS. It
is our hope that, after reading this supplement, you will be better prepared to:
• Recognize the signs and symptoms of ACS, both typical and atypical, and differentiate myocardial ischemia from noncardiac chest pain. • Promptly evaluate and diagnose patients presenting in an urgent care setting to ensure timely initiation of appropriate
treatment. • Effectively manage patients’ care after hospital discharge, continuing or initiating appropriate therapies to reduce the risk of subsequent ischemic events. • Educate patients on the long-term implications of their disease, advise them about necessary lifestyle changes, and counsel them on the importance of adhering to prescribed therapies.
The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Quadrant HealthCom Inc., the U.S. government, or any of its agencies. Some of the drugs or classes of drugs discussed in this supplement may not be listed on the VA national formulary or the DoD basic core formulary or addressed in VHA or DoD treatment guidelines. Please review complete prescribing information for specific drugs or drug combinations—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.
Content of the articles contained in this supplement has been reviewed and approved by the Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.
Access the NEW 2010 DIGITAL Directory
In response to overwhelming demand, the Federal Practitioner 2010
Directory of VA and DoD Health Care Facilities is now available
digitally. Instantly link to the information you need with the virtual
table of contents. Access is free to all who receive the journal and
register here.
Sponsored by the Annenberg Center for Health
Sciences at Eisenhower.
This activity is supported by an educational grant from GlaxoSmithKline.
A maximum of 1 contact hour may be earned for successful completion
of this activity. The activity has been certified for physicians,
pharmacists, nurse practitioners, and nurses. To obtain CE credit,
please print a copy of the supplement and assessment materials, complete
the Post-Test page (page 16) and the Activity Evaluation form (page
17), and return both pages, along with the completed Pre-Test (page
1), to the Annenberg Center for Health Sciences (ACHS #4655), 39000
Bob Hope Drive, Rancho Mirage, CA 92270 or fax to 760-773-4550.
